Compare BridgeBio Pharma Inc (BBIO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs NetEase Inc — how do they compare? BridgeBio Pharma Inc trades at $83.41 (market cap $16.36B), while NetEase Inc trades at $123.19 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 5.1× BridgeBio Pharma Inc's market cap, and NetEase Inc pays a 2.36% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NTES | |
|---|---|---|
Market Cap | $16.36B | $82.75B |
Sector | Health | Media |
52-Week High | $90.17 | $159.34 |
52-Week Low | $47.29 | $109.26 |
Enterprise Value | $18.14B | $59.05B |
Dividend Yield | — | 2.36% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
